Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010032/S251

Quattrode; Octrode; Penta; Lamitrode; Tripole; TriCentrus Lead Extensions

ABBOTT MEDICAL · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONP010032/S251

What did the FDA approve?

The FDA decision dated 2026-09-18 is an approval of supplement P010032/S251 from Abbott Medical, filed under the 30-day notice review track with the reason given as process change affecting manufacturer, sterilizer, packager or supplier. The source statement describes two manufacturing items at Abbott's Arecibo, Puerto Rico facility: optimized process parameter ranges for injection molding equipment used to make Bionate® 55D injection-molded portions at the stimulation and terminal ends of the listed leads and lead extensions, and qualification of a second injection molding machine identical in make, model and configuration to the existing Nissei STX10 machine.

The identifier links this to the original PMA P010032, which the source lists for the product code LGW spinal-cord stimulator category; the action covers the listed leads and extensions rather than the whole system. The statement reports the applicant's stated purposes only. It does not present independent data on safety, performance or clinical outcomes, and none are assessed here. Details such as changed parameter values, qualification test results or the original device scope beyond these fields are absent from the supplied text.

FDA approval order statement

1) optimization of the process parameter ranges of the injection molding equipment used in the manufacturing of the Bionate 55D injection-molded portions at the stimulation and terminal ends of the Quattrode; Octrode; Penta; Lamitrode; Tripole; and TriCentrus Leads and Lead Extensions at the Abbott manufacturing facility in Arecibo, Puerto Rico; and 2) qualification of a second injection molding machine of identical make, model, and configuration to the existing Nissei STX10 Machine at the Abbott manufacturing facility in Arecibo, Puerto Rico.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Neurology
Decision date
Sep 18, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010032/S251
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

For the original device and its historical approval scope, see PMA P010032. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010032 · Original PMA

    GENESIS AND EON FAMILY NEUROSTIMULATION (IPG) SYSTEMS

  2. P010032/S251 received

    Application receipt date recorded by FDA.

  3. P010032/S261 · Related supplement

    Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger

  4. P010032/S251 · FDA decision

    135 Review Track For 30-Day Notice

  5. P010032/S260 · Related supplement

    Proclaim family of SCS IPG

  6. P010032/S265 · Related supplement

    Eterna Spinal Cord Stimulation (SCS) Implantable Pulse Generator

  7. P010032/S262 · Related supplement

    Spinal Cord Stimulation (SCS) External Pulse Generator (EPG)

  8. P010032/S264 · Related supplement

    Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG) Charger

  9. P010032/S266 · Related supplement

    Spinal Cord Stimulation (SCS) Implantable Pulse Generator (IPG)

Timeline entries are records held by MedtechLedger for P010032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010032

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
6901 Preston Rd., Plano, TX, 75024

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records